This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Enayatolah Niakan, MD; Tulio E. Bertorini, MD; Sergio R. Acchiardo, MD; Mary F. Werner, MD

Arch Neurol. 1981;38(6):378-379.

Abstract
• Because procainamide hydrochloride (Pronestyl) may block neuromuscular transmission (NMT), this drug is contraindicated in cases of myasthenia gravis. Reduction of the safety factor of NMT is also seen in other conditions, including peripheral neuropathies. A patient with uremic peripheral neuropathy in whom myasthenia-like weakness developed during procainamide therapy is described. Procainamide should be given with caution in cases of peripheral neuropathies in which there may be a reduction of the safety factor of NMT.

Author Affiliations
From the Departments of Neurology (Drs Niakan and Bertorini), and Medicine (Drs Acchiardo and Werner), Division of Nephrology, The University of Tennessee Center for the Health Sciences, Memphis. Dr Niakan is a clinical fellow of the Muscular Dystrophy Associations of America Inc.

Footnotes
Accepted for publication Oct 27, 1980.

Reprint requests to Department of Neurology, The University of Tennessee Center for the Health Sciences, 956 Court Ave, Memphis, TN 38163 (Dr Bertorini).